Iovance Biotherapeutics, Inc. Earnings

Iovance Biotherapeutics, Inc.’s revenue jumped 15.2% since last year same period to $67.46Mn in the Q3 2025. On a quarterly growth basis, Iovance Biotherapeutics, Inc. has generated 12.52% jump in its revenue since last 3-months.

Iovance Biotherapeutics, Inc.’s net profit fell -9.23% since last year same period to $-91.25Mn in the Q3 2025. On a quarterly growth basis, Iovance Biotherapeutics, Inc. has generated 18.27% jump in its net profits since last 3-months.

Iovance Biotherapeutics, Inc.’s net profit margin jumped 5.18% since last year same period to -135.28% in the Q3 2025. On a quarterly growth basis, Iovance Biotherapeutics, Inc. has generated 27.36% jump in its net profit margins since last 3-months.

Iovance Biotherapeutics, Inc.’s earning per share (EPS) estimates for the current quarter stand at -0.26 - a 6.54% jump from last quarter’s estimates.

Iovance Biotherapeutics, Inc.’s earning per share (EPS) estimates for the current year stand at -0.26.

Iovance Biotherapeutics, Inc.’s earning per share (EPS) jumped 100% since last year same period to 0 in the Q3 2025. This indicates that the Iovance Biotherapeutics, Inc. has generated 100% annual rate of jump in its earning per share (EPS) in the last 4 quarters.